NCT01664910View on ClinicalTrials.gov

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 29, 2012

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic BM transplant

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSC or BM transplant

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Bendamustine Hydrochloride

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Inotuzumab Ozogamicin

Given IV

DRUG

Methotrexate

Given IV

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC transplant

BIOLOGICAL

Rituximab

Given IV

DRUG

Tacrolimus

Given IV or PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01664910 - CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies | Biotech Hunter | Biotech Hunter